#ASCO26: Erleada succeeds in early-stage prostate cancer study, but questions remain
CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday. Treatment with the drug before ...
Johnson & Johnson at #ASCO2026 (Karen Weintraub for Endpoints News) June 1, 2026 06:19 AM EDT R&D J&J's Erleada study succeeds in early-stage prostate cancer, but questions remain Lei Lei Wu News Reporter CHICAGO — As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that